What are Pfizer's main sources of revenue and how diversified are they?

Pfizer's primary revenue stream comes from its Human Health segment, which accounted for 88% of total revenues in 2004. The company also has significant revenue from its Consumer Healthcare (7%) and Animal Health (3.7%) segments. While the Human Health segment is dominant, the company is diversified across these three major areas, with its top 10 pharmaceutical products contributing 69% of Human Health revenues and 61% of total revenues in 2004.

What are the key risks and challenges facing Pfizer according to this filing?

The primary risks identified include increasing competition from generic drug manufacturers due to patent expirations for major products, ongoing patent litigation, and the impact of government regulations and price controls in the U.S. and internationally, particularly concerning Medicare and international healthcare systems. Additionally, the inherent uncertainties and high costs associated with pharmaceutical research and development, and the potential for new competitive product launches, are significant challenges.

How is Pfizer managing its intellectual property and potential loss of patent protection?

Pfizer is actively protecting its intellectual property through a robust patent portfolio. However, it acknowledges the risk associated with patent expirations and faces challenges from generic manufacturers. The company is engaged in legal battles to defend its patents for key drugs and also plans to launch its own generic versions through its Greenstone Ltd. subsidiary when market exclusivity is lost. Furthermore, Pfizer explores strategies like developing OTC versions of its products and leveraging trade secrets to mitigate the impact of patent expirations.

What impact did the acquisitions of Warner-Lambert and Pharmacia have on Pfizer's business?

The acquisition of Warner-Lambert in 2000 was accounted for as a pooling of interests, with financial statements restated. The acquisition of Pharmacia in 2003 was accounted for as a purchase, and its product sales contributed to a full year of revenue in 2004 across all segments, significantly boosting overall revenue growth.

PFE 10-K FY2004 Annual Report — Revenue, Net Income, EPS

Summary

Pfizer Inc.'s 2004 Form 10-K filing highlights a robust financial performance driven primarily by its Human Health segment, which accounted for 88% of total revenues. Key blockbuster drugs like Lipitor, Norvasc, Zoloft, and Celebrex were significant revenue generators, with ten products each exceeding $1 billion in sales. The company also saw strong growth in its Consumer Healthcare and Animal Health segments, with overall revenue increases attributed to strong product performance, the integration of Pharmacia's results, and favorable foreign exchange. However, the filing also underscores the significant challenges ahead. Pfizer is facing increasing competition from generic drug manufacturers, with patent expirations looming for several key products. The company is actively engaged in legal battles to protect its intellectual property. Furthermore, the report details the impact of government regulations, including price constraints and the evolving landscape of the U.S. Medicare program, which could influence future pricing and market access. The company's substantial investment in research and development, while crucial for future growth, also presents inherent risks and uncertainties.

Key Highlights

1Human Health segment generated 88% of total revenues, driven by strong performance from 10 blockbuster drugs, each exceeding $1 billion in sales in 2004.
2The acquisition of Pharmacia Corporation in April 2003 significantly contributed to revenue growth across segments by providing a full year of product sales in 2004.
3Pfizer is experiencing significant competition from generic drug manufacturers, with patent expirations for key products like Zithromax (2005), Zoloft (2006), and Norvasc (2007) posing a challenge.
4The company is actively defending its patents through legal proceedings, particularly for products such as Lipitor, Norvasc, Celebrex, Xalatan, and Detrol, against generic challenges.
5Government regulations and price constraints, especially concerning Medicare and international pricing controls, are identified as significant factors that could impact future financial results.
6Pfizer made substantial investments in research and development, spending $7.7 billion in 2004, to fuel innovation and maintain a pipeline of new molecular entities and product extensions.

PFIZER INC Annual Report, Year Ended Dec 31, 2004

Summary

Key Highlights

Frequently Asked Questions